Healthcare provider profile · identity verified

Pamela Ferry, MD

Family Practice · CONROE, TX · NPI 1881912772

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	137	45
Lisinopril	Lisinopril	104	32
Amlodipine Besylate	Amlodipine Besylate	102	34
Losartan Potassium	Losartan Potassium	101	32
Levothyroxine Sodium	Levothyroxine Sodium	82	29
Gabapentin	Gabapentin	81	21
Pantoprazole Sodium	Pantoprazole Sodium	68	22
Metformin Hcl	Metformin Hcl	64	23
Omeprazole	Omeprazole	56	22
Trazodone Hcl	Trazodone Hcl	56	18
Tramadol Hcl	Tramadol Hcl	52	14
Jardiance	Empagliflozin	51	14
Warfarin Sodium	Warfarin Sodium	49	18
Tizanidine Hcl	Tizanidine Hcl	48	15
Fluticasone Propionate	Fluticasone Propionate	46	17
Ozempic	Semaglutide	45	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	35	14
Hydrochlorothiazide	Hydrochlorothiazide	35	13
Montelukast Sodium	Montelukast Sodium	33	suppressed
Mounjaro	Tirzepatide	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	12
Pregabalin	Pregabalin	31	suppressed
Glipizide Er	Glipizide	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Furosemide	Furosemide	29	13
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Clonazepam	Clonazepam	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	27	14
Prednisone	Prednisone	26	18
Meloxicam	Meloxicam	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	11
Cefdinir	Cefdinir	21	15
Rosuvastatin Calcium	Rosuvastatin Calcium	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Famotidine	Famotidine	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Baclofen	Baclofen	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Finasteride	Finasteride	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Metoprolol Succinate	Metoprolol Succinate	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Atenolol	Atenolol	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	11
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Varenicline Tartrate	Varenicline Tartrate	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Leflunomide	Leflunomide	13	suppressed
Primidone	Primidone	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Valsartan	Valsartan	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Eliquis	Apixaban	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Lactulose	Lactulose	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Naproxen	Naproxen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error